Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest A1C Articles

Preparing for Your Endocrinologist Appointment
Two New Promising Type 2 Drugs in the Pipeline
At the Crossroads, I Choose Insulin
Insulin Linked to Type 2 Weight Gains
Why We Don't Keep Our Dietary Resolutions
How do you evaluate the studies that show that strict control of A1c does not have a beneficial effect on cardiovascular events?
Going for Your Goal
Choosing an Insulin Pump: My Personal Debate
Exenatide Bests Insulin Detemir in Head-to-Head Test
Diabetes and Cancer Together: Which Disease to Address First?
A1C Archives
Browse the A1C Archives
Subscribe to the Community RSS Feed
Print | Email | Share | Comments (0)

Metformin Bests Glipizide in Reducing Cardio Events


Jan 20, 2013

Metformin Bests Glipizide in Reducing Cardio Events

A Chinese research study of diabetes patients with coronary heart disease concludes that metformin is more effective than glipizide in reducing the risk of major cardiovascular events, such as stroke and heart attack.

Researchers at the Shanghai Jiao Tong University School of Medicine studied 304 patients, ages 36 to 80, over a five-year period. The patients were randomly assigned either the sulfonylurea glipizide (30 mg daily) or metformin (1.5 g daily) for three years.

At the start of the study, the baseline A1c for the overall patient group was 7.6%. Within six months, the A1c for the glipizide group fell to 7.1% and to 7.0% for the metformin group.
By the end of the study, 35.1 percent of patients on glipizide had experienced a CV event compared with 25 percent of the patients taking metformin.

Researchers said that this was the first known head-to-head comparison of the two drugs' ability to affect the incidence of CV events. Glipizide, or similar sulfonylureas, and metformin are the drugs doctors are most likely to prescribe to newly diagnosed diabetes patients.

On explanation for metformin's superior performance may be that it has antiatherosclerotic properties-the ability to help blood vessels resist the hardening associated with diabetic inflammation.

An abstract of the study is available online.

Categories: A1C, Diabetes Health, Diabetes Health Magazine, Diabetic, Glipizide, Metformin, Research

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Jan 20, 2013

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.